Navigation Links
Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results
Date:11/18/2009

SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in Korea was a randomized, double-blind, placebo-controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a 4-week non-drug baseline period, 240 men with ED of broad etiology and severity were randomized to one of four treatment groups: Placebo, udenafil 25 mg, udenafil 50 mg or udenafil 75 mg. Patients took one tablet a day for 12 weeks with evaluations every 4 weeks. The primary efficacy endpoint was the change in the standard International Index of Erectile Function (IIEF) Erectile Function Domain (EF) score from baseline to final visit. The secondary efficacy endpoints were the change from the baseline in the mean vaginal penetration success rates and mean intercourse completion rates calculated from the Sexual Encounter Profile (SEP) questions 2 and 3. In addition a sub-group analysis was conducted to determine efficacy in the patients that had lower urinary tract symptoms associated with benign prostatic hyperplasia in addition to erectile dysfunction.

The primary efficacy endpoint for the 50 mg and 75 mg doses were statistically significant compared to placebo. The mean vaginal penetration success rates at 12 weeks (final visit) were 98.7% (75mg) and 90.3% (50mg) and both dose levels were statistically significant compared to placebo (p<0.01). The change from baseline to final visit in the mean intercourse completion rates were 73.5% (75mg) and 51.4% (50mg) significantly (p<0.0001) higher compared to the 23.5% observed in the placebo group. Patients reporting improved erections after the 12-week course of therapy were 88% (75mg), 75% (50mg) and
'/>"/>

SOURCE Dong-A PharmTech Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
2. CardioGenics Holdings Inc. Featured in Medical Device Daily
3. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
4. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
5. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
6. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
7. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
10. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
11. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  Celsion Corporation (NASDAQ: ... Company will host a conference call to discuss ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Thursday, March 12, 2015. To participate in the ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "India Pharma Outlook 2015: Accelerating ... value chain beyond Generics" report to their offering. ... from the slump in the 2013 caused by the ... 2015, growth is expected to continue to be healthy, ...
(Date:3/5/2015)... , March 5, 2015 Mallinckrodt ... global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held ... into a definitive agreement under which a subsidiary of ... Dearborn -led investor group in a transaction valued at ... closing conditions, the parties expect the transaction to be ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9
... Cardica, Inc. (Nasdaq: CRDC ) today announced that it will release ... Tuesday, August 17, 2010 , after the markets close. Cardica,s management will host a conference ... update on the company,s business. , , , ... , , , ...
... 4 PolyGel® is proud to announce that their ThermoActive ™ Cold & Hot ... , , ... , , ... , This is ...
Cached Medicine Technology:Cardica to Announce Fiscal 2010 Fourth Quarter and Year End Financial Results on Tuesday, August 17, 2010 2PolyGel® Receives SADMERC Approval for L-Code L3670 for ThermoActive™ Cold & Hot Mobile Compression Shoulder Orthosis 2
(Date:3/5/2015)... (PRWEB) March 05, 2015 For PASCHA ... and most essential ingredients, the robust flavor of the ... reactions. PASCHA Chocolate is free from peanuts, nuts, ... Experience PASCHA's offering March 6th- 8th at Expo West., ... PASCHA Chocolate has broken new ground with their ...
(Date:3/5/2015)... 05, 2015 Today, Earth Source ... on 100% pollution-free electricity through a partnership with ... As an Arcadia Power Clean Energy Partner, ESO ... Power Partnership requirements, joining national brands such as ... clean energy. Earth Source Organics joins a growing ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Kevin Batsford ... by the grips of drug addiction. The siblings frequented ... their habits, and to seek refuge during the night. ... drugs, without consideration for his outward appearance, hygiene, or ... substances. CNY Central reported on Feb. 23rd ...
(Date:3/5/2015)... March 5, 2015 – As National Patient Safety Awareness ... children’s hospitals around the country are affirming the critical ... safe as possible for their children. , A national ... Safety (SPS) and the Children’s Hospital Association—are collaborating to ... the hospital with their child. , “SPS is ...
(Date:3/5/2015)... March 05, 2015 Considering egg freezing? ... practice, is holding an informational event on ... plan for future families with egg freezing. , What: ... 3500 Peachtree Rd, Atlanta, GA, Time: 5:30 - 7:30 ... RSVP required. Register here ! , In response ...
Breaking Medicine News(10 mins):Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:The Homeless’ Unaddressed Drug Addiction Continues to Spiral Out of Control, Harbor Village Detox Stresses Treatment for the Homeless 2Health News:The Homeless’ Unaddressed Drug Addiction Continues to Spiral Out of Control, Harbor Village Detox Stresses Treatment for the Homeless 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 2Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 3
... and promise of using thermal ablation to target and ... of Vascular and Interventional Radiology ,s August supplement, "Thermal ... Goals and Future Technology." "The Journal ... on the development of multiple medical techniques and devices ...
... Gardner HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay ... go awry in melanoma, scientists have come up with an ... number of patients with advanced melanoma. The drug, PLX4032, ... percent of participants with a particular gene mutation had a ...
... and its Applications (IMA) has been awarded a $20.5-million ... five years. The renewal grant continues the IMA,s tradition ... terms of funding. The IMA, which is part ... Engineering, is one of the world,s premier mathematics institutes ...
... Phillips HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay ... inheritable eye disease that affects 5 percent of U.S. residents ... of the cornea. The genetic disorder, known as ... -- the thin, clear membrane that covers the front of ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you,re ... recall due to salmonella contamination has probably made you refrain from ... now some time has passed, and you,re starting to crave an ... languishing in your fridge or are you inviting a bout of ...
... physical and emotional problems a year after surgery than before ... the key findings of a research study of more than ... Surgery . Researchers from The Netherlands spoke to ... 54, who had undergone planned surgery, ranging from plastic surgery ...
Cached Medicine News:Health News:Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation 2Health News:In Early Trial, Targeted Therapy Fights Advanced Melanoma 2Health News:In Early Trial, Targeted Therapy Fights Advanced Melanoma 3Health News:University of Minnesota math institute receives $20.5 million NSF grant 2Health News:Study Links Gene to Serious Eye Disease 2Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2
Inquire...
... DNA and RNA fragments from 100 bp ... a standard melting temperature multi-purpose agarose that ... Its high gel strength specification ensures that ... during Southern and Northern transfers. UltraPure™ ...
... Agarose with low electroendosmosis ... most DNA/RNA applications. If ... to be used as ... ligase and restriction endonucleases, ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: